TY - JOUR T1 - Do low TB prevalence or lack of BCG Vaccination Contribute to Emergence Multisystem Inflammatory Syndrome? JF - medRxiv DO - 10.1101/2020.07.18.20156893 SP - 2020.07.18.20156893 AU - Tareef Fadhil Raham Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/21/2020.07.18.20156893.abstract N2 - Background Emergence of new multisystem inflammatory syndrome in children (MIS-C) is thought to be associated with COVID-19 pandemic. Covid-19 morbidity and mortality variances among countries has been suggested by previous works to be influenced BCG and previous Latent TB infection (which is reflected by TB prevalence) by possible inducing heterogeneous immunity against SARS-COV2.Aim To examine influence of BCG status and TB prevalence on variances among countries which register new multisystem inflammatory syndrome in children (MIS-C).Methods We choose all countries which report MIS-C till 23/6/2020, number of cases for each 10 million capita was examined among 3 categories of countries classified according to BCG program status. TB prevalence, MIS-C no. / 10 million (M) and Covid-19 deaths/M are taken as markers. Receiver operation characteristic - (ROC) curve, as well as some relative indicators such as (sensitivity and specificity rates), estimation area of trade - off between sensitivity and specificity, and cutoff points are used for discriminating different three pairs of countries (which have different BCG practices). Discrimination of these categories done through studied markers. 95% confidence interval of all probable combinations pairs had been measured.Results MIS-C No/10 M capita in countries never gave BCG vaccination vs countries currently give vaccine shows area under ROC-curve equal to 0.000 with a symbiotic significant of 0.034 and (95% CI interval of 0.000-0.000) also MIS-C No/10 M capita in countries not currently give BCG vaccination (with previous mass vaccination programs) vs countries currently give mass vaccination shows area under ROC-curve equal to 0.094 with a symbiotic significant of 0.027and (95% CI interval of 0.000 -0.280)Important not significant finding in MIS-C No/10 M capita in countries never gave BCG vaccination vs countries not currently give vaccine shows area under ROC-curve equal to 0.583 with a symbiotic significant of 0.683 and (95% CI interval of 0.074-0.759). Countries not currently give vaccine make discrimination in other pairsCOVID-19 deaths M capita in countries never gave BCG vaccination vs countries currently give vaccine shows area under ROC-curve equal to 0.083 with a symbiotic informative and reportable value of 0.077 and (95% CI interval of 0.000-0.309 also COVID-19 deaths M capita in countries not currently give BCG vaccination vs countries currently giving vaccine shows area under ROC-curve equal to 0.188 with a symbiotic informative reportable value of 0.089 and (95% CI interval of 0.000-0.452).Important finding is the not significant association in COVID-19 deaths /M capita in countries never gave BCG vaccination vs countries not currently giving vaccine area under ROC-curve equal to 0.417 with a symbiotic significant of 0.683 and (95% CI interval of 0.078 - 0.755). Countries not currently giving vaccine make discrimination in third pair of countries in significant association and not in 1st pair.Regarding TB prevalence marker or discriminator the areas under curve were informative and reportable and too generating with the leftover markers in all 3 pairs signifying inverse relations with covide-19 mortality and MIS-C no. curves.Conclusion BCG vaccinations and high TB prevalence are found in this study to be related to decrease MIS-C and COVID-19 deaths this might explain variances among countries worldwide. Further studies to confirm this relations and possible relations with other epidemics is recommended. Review of TB programs in relation to treat latent asymptomatic infections and initiate and consolidate BCG programs should be considered urgently.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used are publicAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are available on requist ER -